These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 36206591)

  • 1. Long-acting Injectable Antipsychotics during the COVID-19 pandemic in schizophrenia: An observational study in a real-world clinical setting.
    Barlati S; Nibbio G; Bianchi F; Gigli EBL; Calzavara-Pinton I; Cerati C; Fiori J; Lisoni J; Deste G; Vita A
    Psychiatry Res; 2022 Nov; 317():114878. PubMed ID: 36206591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study.
    McKee KA; Crocker CE; Tibbo PG
    BMC Psychiatry; 2021 Dec; 21(1):633. PubMed ID: 34930204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barriers to Long-acting Injectable Antipsychotic Adherence During the COVID-19 Pandemic: Observations From One Site.
    Forster SE; Gancz NN; Gaither ML; Haas GL; Starver KD; Steinhauer SR
    J Psychiatr Pract; 2022 Nov; 28(6):497-504. PubMed ID: 36355590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach.
    Correll CU; Chepke C; Gionfriddo P; Parks J; Foxworth P; Basu A; Brister TS; Brown D; Clarke C; Hassoun Y
    BMC Psychiatry; 2022 Jan; 22(1):32. PubMed ID: 35012512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
    Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
    J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: A nationwide population-based study.
    Joo SW; Shon SH; Choi G; Koh M; Cho SW; Lee J
    Eur Neuropsychopharmacol; 2019 Sep; 29(9):1051-1060. PubMed ID: 31362852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and economic impact of long-acting injectable antipsychotics in patients previously treated with short-acting oral antipsychotics.
    Kheloussi S; Oberlin J; Trauger M; Testa ND
    J Manag Care Spec Pharm; 2022 Oct; 28(10):1130-1137. PubMed ID: 36125056
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
    García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
    Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
    [No Abstract]   [Full Text] [Related]  

  • 11. Attitudes of European physicians towards the use of long-acting injectable antipsychotics.
    Patel MX; Bent-Ennakhil N; Sapin C; di Nicola S; Loze JY; Nylander AG; Heres S
    BMC Psychiatry; 2020 Mar; 20(1):123. PubMed ID: 32169077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.
    Lin D; Thompson-Leduc P; Ghelerter I; Nguyen H; Lafeuille MH; Benson C; Mavros P; Lefebvre P
    CNS Drugs; 2021 May; 35(5):469-481. PubMed ID: 33909272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
    Nielsen J; Jensen SO; Friis RB; Valentin JB; Correll CU
    Schizophr Bull; 2015 May; 41(3):627-36. PubMed ID: 25180312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness.
    Llorca PM; Abbar M; Courtet P; Guillaume S; Lancrenon S; Samalin L
    BMC Psychiatry; 2013 Dec; 13():340. PubMed ID: 24359031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-generation long-acting injections anti-psychotics improve executive functions in patients with schizophrenia: a 12-month real-world study.
    Magliocco F; de Filippis R; Aloi M; Staltari FA; Gaetano R; Segura-Garcia C; De Fazio P
    Int J Psychiatry Clin Pract; 2020 Jun; 24(2):201-207. PubMed ID: 32134336
    [No Abstract]   [Full Text] [Related]  

  • 16. Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia.
    Fu AZ; Pesa JA; Lakey S; Benson C
    BMC Psychiatry; 2022 Apr; 22(1):250. PubMed ID: 35395757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switch from Olanzapine Long-Acting Injectable to its Oral Equivalent during COVID-19 Pandemic: a Real World Observational Study.
    Miron AA; Teodorescu A; Ifteni P; Irimie CA; Dima L; Petric PS
    Psychiatr Q; 2022 Jun; 93(2):627-635. PubMed ID: 35235126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of long acting injectable antipsychotic use and associated clinical factors in schizophrenia among 15 Asian countries and region.
    Tang CT; Chua EC; Chew QH; He YL; Si TM; Chiu HF; Xiang YT; Kato TA; Kanba S; Shinfuku N; Lee MS; Park SC; Park YC; Chong MY; Lin SK; Yang SY; Tripathi A; Avasthi A; Grover S; Kallivayalil RA; Udomratn P; Chee KY; Tanra AJ; Rabbani MG; Javed A; Kathiarachchi S; Waas D; Myint WA; Sartorius N; Tran VC; Nguyen KV; Tan CH; Baldessarini RJ; Sim K
    Asia Pac Psychiatry; 2020 Dec; 12(4):e12393. PubMed ID: 32468725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
    Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
    J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) study: real-world clinical practice in schizophrenia.
    Joshi K; Mao L; Biondi DM; Millet R
    BMC Psychiatry; 2018 Jan; 18(1):24. PubMed ID: 29378547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.